PAVmed Inc. (NASDAQ:PAVM) stock rose Wednesday following the announcement that its subsidiary, Lucid Diagnostics Inc. (NASDAQ:LUCD), has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard Esophageal DNA Test.

This news is contributing to the stock’s impressive daily gain as broader markets are experiencing positive momentum, with the Nasdaq up 0.70%.

Lucid Diagnostics Secures VA Contract for EsoGuard

Lucid Diagnostics’ contract expands access to esophageal precancer testing across the VA’s healthcare system, which serves over nine million veterans annually. The contract includes pre-negotiated pricing that aligns with Medicare payment rates, enabling VA facilities to procure EsoGuard through a streamlined process.

This partnership highlights the strength of the clinical evidence supporting EsoGuard, as stated by Shaun O’Neil, President and COO of Lucid Diagnostics. The company aims to integrate EsoGuard into standard clinical practice across various healthcare systems, enhancing cancer prevention efforts.

The broader market is up, with the S&P 500 gaining 0.66% today. PAVmed’s rise aligns with this positive market sentiment, suggesting the stock is moving in step with broader trends.

PAVM Shows Strong Technical Indicators

PAVmed is currently trading 167.1% above its 20-day simple moving average (SMA) and 84.9% above its 100-day SMA, demonstrating significant short-term strength. Over the past 12 months, shares have increased by 8.05% and are currently positioned closer to their 52-week highs than lows.

The RSI is at 35.62, which is considered neutral territory, while the MACD is above its signal line, indicating bullish momentum. The combination of neutral RSI and bullish MACD suggests mixed momentum.

• Key Resistance: $25.00
• Key Support: $17.00

Anticipation Builds for PAVM’s Earnings Report

Investors are looking ahead to the next earnings report on March 24, 2026.

• EPS Estimate: $-4.62 (Down from $-1.80 YoY)
• Revenue Estimate: $0.03 million (Up from $0.01 million YoY)

Analyst Consensus & Recent Actions:

The stock carries a Buy Rating with an average price target of $755.53. Recent analyst moves include:

• Ascendiant Capital: Buy (Lowered Target to $17.00) (December 10, 2025)

PAVM Scores High on Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for PAVmed, highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Bullish (Score: 89/100) — Stock is outperforming the broader market.
• Value: Risk (Score: 4/100) — Trading at a steep premium relative to peers.
• Growth: Strong (Score: 77/100) — Indicates potential for future expansion.

The Verdict: PAVmed’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the Momentum (89) confirms the strong trend, the extremely low Value (4) score warns that the stock is priced for perfection—investors should ride the trend but use tight stop-losses.

Price Action: PAVmed shares were up 291.11% at $17.80 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock